Tech Company Financing Transactions
Kyverna Therapeutics Funding Round
Kyverna Therapeutics, operating out of Berkeley, secured $25 million from Gilead Sciences, Vida Ventures and Westlake Village BioPartners.
Transaction Overview
Company Name
Announced On
1/14/2020
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Kyverna's therapeutic strategy which combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Undisclosed
Website
Email Address
Overview
We are a cell therapy company developing a new class of treatments and potential cures for serious autoimmune diseases. Autoimmune diseases result from a failure of the immune system to distinguish self from non-self, caused by autoreactive B cells and T cells attacking the body's own tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dominic Borie
Chief Scientific Officer
Jeffrey Greve
VP - General Counsel
Gregory Giotta
VP - Operations
Ryan Jones
Browse more venture capital transactions:
Prev: 1/14/2020: Vesta Healthcare venture capital transaction
Next: 1/14/2020: Codagenix venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs